Andarine (developmental code names GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy (BPH),using the nonsteroidal antiandrogen bicalutamide as a lead compound.
Andarine attaches to proteins in the body known as androgen receptors. When andarine binds to these receptors, it tells the muscles and bones in the body to grow. Unlike some other chemicals that bind to androgen receptors, such as steroids, andarine doesn't seem to cause as many side effects in other parts of the body.
